Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Regeneron Pharmaceuticals REGN in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 6 | 3 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 3 | 1 | 2 | 1 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Regeneron Pharmaceuticals, presenting an average target of $1069.69, a high estimate of $1229.00, and a low estimate of $720.00. This upward trend is evident, with the current average reflecting a 0.87% increase from the previous average price target of $1060.44.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1229.00 | $1229.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $1150.00 | $1050.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1229.00 | $1200.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1200.00 | $1185.00 |
| Cory Kasimov | Evercore ISI Group | Announces | Outperform | $1150.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $925.00 | $925.00 |
| Tyler Van Buren | TD Cowen | Raises | Buy | $1030.00 | $1020.00 |
| Colin Bristow | UBS | Raises | Buy | $1099.00 | $1090.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $925.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Neutral | $925.00 | - |
| Geoff Meacham | B of A Securities | Raises | Underperform | $720.00 | $710.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1189.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $1135.00 | $1135.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regeneron Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Regeneron Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Regeneron Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Regeneron Pharmaceuticals analyst ratings.
Get to Know Regeneron Pharmaceuticals Better
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Financial Milestones: Regeneron Pharmaceuticals's Journey
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining Regeneron Pharmaceuticals's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -0.54% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Regeneron Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.96% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.73%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.14%, the company showcases efficient use of assets and strong financial health.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
